This HTML5 document contains 46 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
wdthttp://www.wikidata.org/prop/direct/
wdtnhttp://www.wikidata.org/prop/direct-normalized/
schemahttp://schema.org/
rdfshttp://www.w3.org/2000/01/rdf-schema#
skoshttp://www.w3.org/2004/02/skos/core#
wikibasehttp://wikiba.se/ontology#
phttp://www.wikidata.org/prop/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n12http://rdf.ncbi.nlm.nih.gov/pubchem/reference/
xsdhhttp://www.w3.org/2001/XMLSchema#
n8http://dx.doi.org/10.1002/
wdshttp://www.wikidata.org/entity/statement/
wdhttp://www.wikidata.org/entity/

Statements

Subject Item
wd:Q61831134
rdf:type
wikibase:Item
schema:description
article наукова стаття, опублікована в лютому 1997 im Februar 1997 veröffentlichter wissenschaftlicher Artikel wetenschappelijk artikel article scientifique publié en 1997
p:P577
wds:Q61831134-2B4256FF-F4C3-4FF8-83F1-5A1E0564A601
wdt:P577
1997-02-01T00:00:00Z
p:P2093
wds:Q61831134-7F676BB4-64C7-4905-B18D-B280F7CF695C wds:Q61831134-870C6786-615D-419D-AD58-7815C87F9097 wds:Q61831134-782B5705-76B5-4560-95A5-5436873D5D1A
wdt:P2093
S J Litchfield R C Littleford M McLaren
rdfs:label
OralL-arginine supplementation and cutaneous vascular responses in patients with primary Raynaud's phenomenon OralL-arginine supplementation and cutaneous vascular responses in patients with primary Raynaud's phenomenon
skos:prefLabel
OralL-arginine supplementation and cutaneous vascular responses in patients with primary Raynaud's phenomenon OralL-arginine supplementation and cutaneous vascular responses in patients with primary Raynaud's phenomenon
schema:name
OralL-arginine supplementation and cutaneous vascular responses in patients with primary Raynaud's phenomenon OralL-arginine supplementation and cutaneous vascular responses in patients with primary Raynaud's phenomenon
p:P50
wds:Q61831134-F0CD9FB2-4A2C-48E6-9E95-4288B2B0D162 wds:Q61831134-0D47D1E9-E31D-4655-BE76-7CA0BC3EF1E3 wds:Q61831134-796139D1-3FA2-4A94-8EC2-1B88D8F5874B
wdt:P50
wd:Q40024976 wd:Q55686130 wd:Q34004167
p:P1476
wds:Q61831134-F0CFDBDD-1FD2-4885-B0C3-C2FA437BEF58
wdt:P1476
Oral L-arginine supplementation and cutaneous vascular responses in patients with primary Raynaud's phenomenon
p:P304
wds:Q61831134-6CED206C-3CD9-4DC7-AB88-ADA413738B3C
wdt:P304
352-357
p:P31
wds:Q61831134-98D249CF-C4BF-4E31-90D9-60A9A0AF87A8
wdt:P31
wd:Q13442814
p:P921
wds:Q61831134-912532F1-75D3-43F3-9223-C7726B256429
wdt:P921
wd:Q327657
p:P698
wds:Q61831134-F27A97D0-1E86-4CC3-938E-E1E163B9047B
wdtn:P698
n12:9041947
wdt:P698
9041947
p:P1433
wds:Q61831134-964E689A-F7C7-4FFB-B3DC-3A6F5FC8421A
wdt:P1433
wd:Q23929027
p:P433
wds:Q61831134-96F9C400-A516-4DEB-AB42-18B1B4095432
p:P478
wds:Q61831134-9BA28913-3C24-4D6E-8C49-B1FF4D803E0F
wdt:P433
2
wdt:P478
40
p:P356
wds:Q61831134-46F0E349-08F1-4FDE-89C9-77A128F44FA6
wdtn:P356
n8:ART.1780400220
wdt:P356
10.1002/ART.1780400220